Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
Alkermes rebuffed by FDA on antidepressantAlkermes is facing a significant delay for its ALKS 5461 candidate for major depressive disorder after the FDA Share XAlkermes rebuffed by FDA on antidepressanthttps://pharmaphorum.com/news/alkermes-rebuffed-by-fda-on-antidepressant/
Alkermes/Biogen hope for less tummy trouble with new MS pillAlkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat Share XAlkermes/Biogen hope for less tummy trouble with new MS pillhttps://pharmaphorum.com/news/alkermes-biogen-hope-for-less-tummy-trouble-with-new-ms-pill/
Alkermes preps filing for weight-friendly schizophrenia drugAlkermes is planning to head to the FDA next year with a new schizophrenia drug that, according to Share XAlkermes preps filing for weight-friendly schizophrenia drughttps://pharmaphorum.com/news/alkermes-preps-filing-for-weight-friendly-schizophrenia-drug/
FDA panel backs Sage’s novel antidepressant but turns down Alkermes’Sage’s Zulresso (brexanolone) is on course for approval for postnatal depression in the US after a positive vote Share XFDA panel backs Sage’s novel antidepressant but turns down Alkermes’https://pharmaphorum.com/news/fda-panel-backs-sages-novel-antidepressant-but-turns-down-alkermes/
Alkermes closing in on Biogen with MS rivalALKS 8700 may have fewer side effects than Tecfidera. Share XAlkermes closing in on Biogen with MS rivalhttps://pharmaphorum.com/news/alkermes-closing-biogen-ms-challenger/